Back
Open Access

Introduction - PCSK9 inhibitors: the next chapter in CVD prevention.

Session: Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: the next chapter in cardiovascular disease prevention
Topic: Atherosclerosis
Sponsored by Amgen GmbH.
Event: ESC Congress 2017

Congress Presentation

Add to my library

Like

4 more presentations in this session

CVD prevention and event reduction.

Speaker: Professor M. Sabatine (Boston, US)

Access
Like
Thumbnail

Future perspectives in lipid lowering and CVD prevention.

Speaker: Professor P. Sever (London, GB)

Access
Like
Thumbnail

Panel discussion - PCSK9 inhibitors: the next chapter in CVD prevention.

Speaker: Professor J. Chapman (Paris, FR)

Access
Like
Thumbnail

Close - PCSK9 inhibitors: the next chapter in CVD prevention.

Speaker: Professor J. Chapman (Paris, FR)

Access
Like
Thumbnail

Access the full session

Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: the next chapter in cardiovascular disease prevention

Speakers: Professor M. Sabatine, Professor P. Sever, Professor J. Chapman, Professor J. Chapman
Access
Like
Thumbnail

About the event

Image

ESC Congress 2017

26 August - 30 August 2017

Sessions Presentations

Congress
logo Image

ESC 365 is supported by

logo Bristol Myers Squibb Explore sponsored resources
logo Novo Nordisk Explore sponsored resources